Related Experiment Video
Updated: Apr 20, 2026
Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
Published on: April 26, 2019
SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma
Mélanie Menara1, Lindsey Oudijk, Cécile Badoual
1INSERM (M.M., C.B., C.L-L., L.A., A-P.G-R., J.F.), UMR U970, Paris Cardiovascular Research Center-PARCC, F-75015 Paris, France; Université Paris Descartes (M.M., C.B., J.B., C.L-L., L.A., M.S., A-P.G-R., J.F.), Sorbonne Paris Cité, Faculté de Médecine, F-75006 Paris, France; Department of Pathology (L.O., R.d.K.), Erasmus MC Cancer Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Département d'Anatomo-Pathologie (C.B.), Services d'Hypertension Artérielle (L.A.), Chirurgie Digestive (F.Z.), and Génétique (A-P.G-R.), F-75015 Paris, France; Assistance Publique-Hôpitaux de Paris (J.B.), Hôpital Cochin, Centre de Référence Maladies Rares de la Surrénale, Service des Maladies Endocriniennes et Métaboliques, F-75014 Paris, France; INSERM (J.B.), U1016, CNRS UMR8104, Département d'Endocrinologie, Métabolisme and Cancer, Institut Cochin, F-75014 Paris, France; Rare Adrenal Cancer Network-Cortico Médullosurrénale Tumeur Endocrine (J.B., A-P.G-R.), Institut National du Cancer, F-75014 Paris, France; Collège de France (X.I.), Centre Interdisciplinaire de Recherche en Biologie, F-75005 Paris, France; INSERM U1050 (X.I.), F-75005 Paris, France; and CNRS UMR7241 (X.I., M.S.), F-75005 Paris, France.
Context:
Pheochromocytomas (PCC) and paragangliomas (PGL) may be caused by a germline mutation in 12 different predisposing genes. We previously reported that immunohistochemistry is a useful approach to detect patients harboring SDHx mutations. SDHA immunostaining is negative in SDHA-mutated tumors only, while SDHB immunostaining is negative in samples mutated on all SDHx genes. In some cases of SDHD or SDHC-mutated tumors, a weak diffuse SDHB labeling has however been described.
Objective:
Here, we addressed whether the same procedure could be applicable to detect patients with germline SDHD mutations, by testing two new commercially available anti-SDHD antibodies.
Design And Methods:
We performed a retrospective study on 170 PGL/PCC in which we investigated SDHD and SDHB expression by immunohistochemistry.
Results:
SDHx-mutated PGL/PCC showed a completely negative SDHB staining (23/27) or a weak cytoplasmic background (4/27). Unexpectedly, we observed that SDHD immunohistochemistry was positive in SDHx-deficient tumors and negative in the other samples. Twenty-six of 27 SDHx tumors (including the four weakly stained for SDHB) were positive for SDHD. Among non-SDHx tumors, 138/143 were positive for SDHB and negative for SDHD. Five cases showed a negative immunostaining for SDHB, but were negative for SDHD.
Conclusion:
Our results demonstrate that a positive SDHD immunostaining predicts the presence of an SDHx gene mutation. Because SDHB negative immunostaining is sometimes difficult to interpret in the case of background, the addition of SDHD positive immunohistochemistry will be a very useful tool to predict or validate SDHx gene variants in PGL/PCC.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022